Dr. Jessica Cande

Associate
Full contact info

Experience

EsoBiotec Announces up to $1 Billion Acquisition by AstraZeneca

March 17, 2025

Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.

Read more

Related contacts

Rama Padmanabhan
Partner, San Diego
Rowook Park
Partner, San Diego
Charity Williams
Partner, San Diego
Simon Amies
Partner, London
Russell Anderson
Partner, London
Megan Browdie
Partner, Washington, DC
Ross Eberly
Partner, Santa Monica
Christopher Kimball
Partner, Washington, DC
Charlie Lightfoot
Partner, London
Alessandra Murata
Partner, Palo Alto
Dr. Matthew Pavao
Partner, Boston
Guadalupe Sampedro
Partner, London
Stella Sarma
Partner, Brussels
Leo Spicer-Phelps
Partner, London
Nicola Squire
Partner, London
Chris Stack
Partner, London
Jeffrey J. Tolin
Partner, New York
David Wilson
Partner, London
Julia R. Brinton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Jack Jones
Special Counsel, London
Dillon Martinson
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Julie Wicklund
Special Counsel, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Kafeel Azher
Associate, London
Sarah Buchik
Associate, New York
Dr. Jessica Cande
Associate, Boston
Mari Dugas
Associate, Washington, DC
Michael Fernando
Associate, London
Athina Gaki
Associate, Brussels
Elaine Huang
Associate, Palo Alto
Mark Jones
Associate, London
Eerik Kukebal
Associate, London
Chris Lynn
Associate, London
Morgan McCormack
Associate, London
Daniel Millard
Associate, London
Lindsey O'Crump
Associate, Washington, DC
Alexandra Paterson
Associate, London
Dr. Robert E. Powers
Associate, Boston
Zhijing Yu
Associate, Singapore
Kevin Gurley
Quantitative Analyst, New York

Related Practices & Industries

Autolus Announces Strategic Collaboration With BioNTech, $350 Million Underwritten Offering

February 8, 2024

Cooley advised Autolus – a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies – on its strategic collaboration with BioNTech, an immunotherapy company pioneering novel therapies for cancer and other serious diseases, to advance both companies’ autologous CAR-T programs toward commercialization, as well as a $350 million underwritten offering.

Read more

Related contacts

Kenneth Krisko
Partner, Reston
Stephanie Parker Palmer
Special Counsel, Reston
Carly Robinson
Associate, Reston
Joe Sandys
Special Counsel, London
Alexandra Paterson
Associate, London
Christian Plaza
Partner, Reston
Courtney Thorne
Partner, London
Brian Leaf
Partner, Reston
William DuVal
Special Counsel, Reston
Trevor Bossi
Associate, Boston
Tyler Day
Associate, Reston
Claire Keast-Butler
Co-Partner in Charge – London, London
Mandy Ching
Associate, London
Megan Browdie
Partner, Washington, DC
Ann Bevitt
Partner, London
John Clark
Partner, London
Kevin King
Partner, Washington, DC
Dr. Matthew Pavao
Partner, Boston
Barbara Borden
Senior Counsel, San Diego
David Wilson
Partner, London
Christine Graham
Special Counsel, London
Rebecca Ross
Special Counsel, Washington, DC
Rebecca Ross
Special Counsel, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Jacqueline Moore
Special Counsel, London
Jack Jones
Special Counsel, London
Rubin Waranch
Associate, Colorado
Dr. Jessica Cande
Associate, Boston
Anna Caro
Associate, London
Eerik Kukebal
Associate, London
Matthew S. Scarano
Associate, San Diego
Margaux Arntson
Associate

Related Practices & Industries

Admissions and credentials

Massachusetts